In brief: National Institute for Clinical Excellence

The National Institute for Clinical Excellence has ruled that taxanes Taxotere and Taxol can be used to treat advanced breast cancer where other drugs have not worked or are unsuitable. The Association of the British Pharmaceutical Industry welcomed the decision , but said it should have been reached without the ...

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here